A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Inclusion Criteria:

• Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).

• Agreement to use contraception.

• Willing and able to comply with the study protocol and procedures.

• Further inclusion criteria apply.

Exclusion Criteria:

• Participation in the extension study could expose the participant to an undue safetyrisk.

• Women who are pregnant (or who are considering pregnancy) or breastfeeding.

• Further exclusion criteria apply.